November 14th 2023
We’ve compiled a list of key food safety tips that you need to know in order to have a safe, bacteria-free holiday.
September 8th 2022
Medical Crossfire®: Which Patients with Hematologic Malignancies are at Risk for Secondary Immunodeficiency (SID)… and How Can We Leverage Evidence to Improve Their Outcomes?
View More
Addressing Healthcare Inequities™ in Glaucoma Management – Understanding Challenges in Segmented Patient Populations (CME Track)
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
October 26, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Patient, Provider, and Caregiver Connection™: Prevention and Control of Meningococcal Disease — Individualizing Vaccine Recommendations in Adolescent Populations
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Addressing Healthcare Inequities: Bridging the Gap in Multiple Sclerosis – A Focus on Clinical and Healthcare Disparities in Black Patients
View More
Overcoming Racial Disparities in Multiple Myeloma Outcomes and Clinical Trials: How We are Moving Care Forward Today
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
AstraZeneca COVID-19 Vaccine Linked to Rare Thrombosis, Thrombocytopenia Events
April 9th 2021The newest research of rare adverse events among patients administered the vaccine highlights that venous or arterial thrombosis can develop in unexpected regions, including the brain or abdomen, 5-20 days after administration.
Read More
NIAID, Review Board Challenges New AstraZeneca COVID-19 Vaccine Data
March 23rd 2021A statement hours after the company reported promising interim phase 3 data stated the Data Safety and Monitoring Board believes they included outdated data “which may have provided an incomplete view of the efficacy data.”
Read More